A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Bladder Cancer
- Breast Cancer
- Cutaneous T Cell Lymphoma
- Melanoma
- Merkel Cell Carcinoma
- Prostate Cancer
- Renal Cancer
- Sarcoma
- Solid Tumor
- Testicular Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02643303
- Collaborators
- MedImmune LLC
- Cancer Research Institute, New York City
- Investigators
- Study Chair: Craig L Slingluff, Jr., MD University of Virginia Study Chair: Nina Bhardwaj, MD, PhD Tisch Cancer Institute Ichan School of Medicine at Mount Sinai
Get Well Soon